Why PROCEPT BioRobotics (PRCT) is back in focus

PROCEPT BioRobotics (PRCT) is drawing attention after reporting first quarter 2026 results, with sales of US$83.13 million alongside a net loss of US$31.64 million and a basic loss per share of US$0.56.

The earnings release has landed against a weak share price backdrop, with the latest share price at US$24.63 and a year to date share price return of 19.93% decline alongside a 1 year total shareholder return of 55.72% decline. This suggests recent selling pressure and increased focus on rising losses despite sales growth.

If this mix of growth and risk has your attention, it can be useful to compare it with other robotics themed names by scanning 33 robotics and automation stocks

With PROCEPT BioRobotics now valued at about US$1.37b and trading at US$24.63, the key question is whether recent share price weakness leaves potential upside on the table or if the market is already pricing in future growth.

Most Popular Narrative: 19.1% Undervalued

With PROCEPT BioRobotics last closing at $24.63 and the most followed fair value narrative sitting at $30.44, the gap between price and story is clear and substantial.

Ongoing positive clinical trial progress (including WATER IV for prostate cancer) and anticipated future approvals for new indications will expand the total addressable market, catalyzing higher system placements, greater procedure volumes, and improved long-run profitability as new patient populations are reached.

The narrative leans heavily on strong revenue expansion, rising margins and a richer earnings profile carved out over several years. It hinges on Aquablation moving deeper into hospitals, the maturation of international accounts, and profitability metrics shifting closer to established medical equipment peers. Curious which growth, margin and valuation assumptions need to align for today’s $30.44 fair value to hold?

Result: Fair Value of $30.44 (UNDERVALUED)

However, heavy reliance on Aquablation and continued operating losses mean any slowdown in adoption or tighter reimbursement could quickly undermine this underpriced growth story.

Next Steps

The mixed tone of growth potential and real risk in this story is hard to ignore, so if it feels finely balanced, act quickly, review the figures yourself, and then weigh up the 1 key reward and 2 important warning signs

Looking for more investment ideas?

If PRCT has sharpened your thinking, do not stop here. Widen your watchlist with other ideas so you are not relying on a single story.

• Spot potential bargains early by scanning companies that screen as attractively priced with solid fundamentals using the 51 high quality undervalued stocks.
• Prioritise resilience by checking out companies with strong financial footing through the solid balance sheet and fundamentals stocks screener (45 results).
• Hunt for under followed opportunities by reviewing the screener containing 25 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.